iCo Therapeutics Welcomes Dr. David S. Boyer to Strategic Advisory Board

Oct 27, 2006, 01:00 ET from iCo Therapeutics Inc.

    VANCOUVER, Oct. 27 /PRNewswire/ - iCo Therapeutics Inc. announced today
 that Dr. David S. Boyer will join its strategic advisory team. As an
 ophthalmologist and senior partner of the Retina-Vitreous Associates
 Medical Group in California, Dr. Boyer specializes in diseases of the
 retina and vitreous. He is a Clinical Associate Professor of Ophthalmology
 at the University of Southern California and has worked on trials for
 age-related macular degeneration, diabetic retinopathy, and cytomegalovirus
     "We are pleased to have Dr. Boyer join our advisory team," said Andrew
 Rae, iCoTherapeutics' President and Chief Executive Officer. "His clinical
 knowledge and experience as an advisor to dynamic and successful
 biotechnology companies brings strength to our strategic advisory team."
     Dr. Boyer has served on the advisory boards for Alcon, Novartis,
 Eyetech/Pfizer, Genentech, Neurotech and the Macular Degeneration
 Partnership. He is a reviewer for several ophthalmology and diabetes
 medical publications including Archives of Ophthalmology, American Journal
 of Ophthalmology, Diabetes Care, and Ophthalmology.
     Throughout his career, Dr. Boyer has been honoured by prestigious
 organizations including the American Academy of Ophthalmology (Board of
 Trustees Honor Award Certificate) and Retinitis Pigmentosa International
 (1996 Jules Stein Living Tribute Award). Every year since 2000, he has been
 selected by his peers to be listed in Best Doctors In America.
     Dr. Boyer's professional affiliations include the Los Angeles Medical
 Association, Los Angeles Eye Society, American Board of Ophthalmology,
 Discovery Fund for Eye Research, American Academy of Ophthalmology and
 Otolaryngology, California Medical Association, Vitreous Society, American
 Medical Association, Retinitis Pigmentosa International, and the American
 Diabetes Association. Dr. Boyer earned his medical degree at Chicago
 Medical School, completed his internship and residency at the USC/Los
 Angeles County Medical Center, and went on to do his fellowship in retinal
 surgery at the Wills Eye Hospital in Philadelphia.
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new
 conditions affecting isolated biological environments - areas such as the
 eye, spinal cord, or joints - where locally-administered application of
 these therapies would have minimal systemic distribution and fewer safety
     For more information, visit the company website at:
     CONTACT: Business Development Contact: Dr. John Clement, CT&DO, (778)
 688-0644; Finance/Investor Contact: Mr. John Meekison, CFO, (604) 602-9414;
 Media Contact: Amanda Smith, Principal, Smith Biotech, (778) 846-4116

SOURCE iCo Therapeutics Inc.